Mark Olsen to Cohort Studies
This is a "connection" page, showing publications Mark Olsen has written about Cohort Studies.
Connection Strength
0.114
-
Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920. Cancer. 2022 03 01; 128(5):966-974.
Score: 0.041
-
Safety and Efficacy of Nivolumab in Patients With Advanced Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study. Clin Genitourin Cancer. 2020 12; 18(6):469-476.e4.
Score: 0.037
-
Safety and Efficacy of Nivolumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study. Clin Genitourin Cancer. 2020 12; 18(6):461-468.e3.
Score: 0.037